Cutting-edge immunoassay solutions

Large Molecule Bioanalysis

Why choose us?

- Method Development, Transfer and Validation
- Regulated GLP Pre-clinical and Clinical GCP sample analysis
- Pharmacokinetic (PK) & Toxicokinetic (TK) analysis
- Pharmacodynamic (PD) Biomarker analysis
- Immunogenicity Anti-Drug Antibody (ADA)
- Expertise, customisation, flexibility, and speed

Comprehensive Expertise

Using a wide range of techniques, robust methodology, and cutting-edge technology, Unilabs Pharma Solutions deliver scientific innovations that solve your large molecule challenges. We are adept at handling many large molecule therapeutics, including monoclonal antibodies, fusion proteins, antibody-drug conjugates, bi/tri-specific antibodies, reagent labelling and more.

Swift Turnaround

Benefit from the efficient turnaround times and scientifically validated, reproducible results of our bioanalytical services critical during first in-human clinical studies. We understand the urgency of your research and ensure timely delivery of results. Over 95% of clients who participated in our 2024 satisfaction survey would recommend Unilabs' services.

Rigorous Compliance

We adhere to GLP, GCP, CLIA and ISO 15189 regulations, upholding the highest analytical standards in the industry.

Our team possesses expert knowledge of regulatory guidelines, including FDA, EMA, and ICH, for bioanalytical testing.

Pharmacodynamic Biomarker Analysis

A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes or responses to an exposure or intervention, including therapeutic interventions.

Our team can develop and validate highly-sensitive assays for protein, genetic, or metabolic biomarkers.

Pharmacokinetic and Toxicokinetic Analysis

Our bioanalytical scientists are highly skilled experts in ligand binding assays, utilising ELISA and MSD platforms.

They quantify drug levels in biological samples for crucial PK/TK data.

Anti-Drug Antibody Analysis

The immunogenic potential of a biotherapeutic is measured using ADA testing in a tiered approach: initial screening, confirmatory, and titre experiments, with statistical analysis to support cut point calculations.

Scan the QR code to contact us